Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study. Ni M, Zhou L, Lu Y, Guo D, et al. BMC Cancer 2024;24:1214.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ni M, Zhou L, Lu Y, Guo D, et al. Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study. BMC Cancer 2024;24:1214.
PMID: 39350055